Company profile: Omeros
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARΞ³ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
Products and services
- Narsoplimab (OMS721): Human monoclonal antibody targeting MASP-2, used to treat TA-TMA and lupus nephritis by inhibiting the lectin pathway of the complement system
- OMS1029: Long-acting second-generation antibody targeting MASP-2, designed for monthly to quarterly dosing to treat lectin pathway disorders via sustained lectin complement pathway inhibition
- OMS906: Humanized monoclonal antibody targeting MASP-3, treating paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders by inhibiting the alternative complement pathway
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Omeros
Pearl Therapeutics
HQ: United States
Website
- Description: Provider of unique dual and triple combination inhaled therapies for widely prevalent respiratory diseases, including chronic obstructive pulmonary disease, delivered via familiar metered dose inhalers to broaden patient access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Pearl Therapeutics company profile β
Jnana Therapeutics
HQ: United States
Website
- Description: Provider of chemoproteomics-driven drug discovery via its RAPID platform to identify small-molecule medicines for a range of diseases; developing JNT-517, an allosteric SLC6A19 inhibitor for phenylketonuria to reduce plasma phenylalanine; advancing programs for autoimmune and inflammatory conditions; and collaborating with biopharma in cancer, immune-mediated, and neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Jnana Therapeutics company profile β
Antibe Therapeutics
HQ: Canada
Website
- Description: Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Antibe Therapeutics company profile β
Exzell Pharma
HQ: Canada
Website
- Description: Provider of medicines, healthcare and biopharma-based products, including EsopH OTC therapy for GERD that relieves heartburn and can be used with PPI prescriptions; Swiss Natural vitamins, supplements and minerals from natural sources; Salinex nasal spray to hydrate and cleanse; PediaVit vitamins and iron for infants and children; Koena multi-strain probiotics; and Ozonol ointment for scrapes, minor burns, and skin irritations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Exzell Pharma company profile β
CohBar
HQ: United States
Website
- Description: Provider of mitochondria-based therapeutics as a clinical-stage biotechnology company developing CB4211 for NASH and obesity, showing reduced liver damage biomarkers and glucose levels; CB5138 analogs in preclinical development for IPF and other fibrotic diseases, reducing lung fibrosis and inflammation; and a Mitochondrial Genome Mining platform to discover therapeutic peptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full CohBar company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Omeros
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Omeros
2.2 - Growth funds investing in similar companies to Omeros
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Omeros
4.2 - Public trading comparable groups for Omeros
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β